Minimally Invasive Hyperthermic Intraperitoneal Perfusion for Gastric Cancer

  • Timothy E. Newhook
  • Brian BadgwellEmail author


Patients diagnosed with stage IV gastric adenocarcinoma have traditionally been offered definitive chemotherapy or best supportive care. However, patients with metastases restricted to the peritoneal cavity, either with carcinomatosis or positive peritoneal cytology, may represent a population with further therapeutic options. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to be a safe operation for patients with carcinomatosis and positive peritoneal cytology from metastatic gastric adenocarcinoma and may lead to gastrectomy for select patients. Direct application of cytotoxic therapy to the peritoneum via HIPEC has been traditionally performed via laparotomy and has led to high morbidity. This innovative minimally invasive approach for select patients with metastatic gastric adenocarcinoma presents an opportunity for further treatment options with much lower morbidity.


Hyperthermic intraperitoneal chemotherapy HIPEC Gastric cancer Laparoscopic HIPEC 


  1. 1.
    Ikoma N, Chen HC, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679.CrossRefGoogle Scholar
  2. 2.
    Badgwell B, Blum M, Estrella J, et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. J Am Coll Surg. 2015;221(1):83–90.CrossRefGoogle Scholar
  3. 3.
    National Comprehensive Cancer Network Guidelines Version 1.2017. Gastric Cancer. Available at Accessed 1 May 2017.
  4. 4.
    Amin MB, et al., editors. American joint commission on cancer, staging manual, eighth edition. Stomach Cancer, p. 203–220.Google Scholar
  5. 5.
    Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:4332.CrossRefGoogle Scholar
  6. 6.
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.CrossRefGoogle Scholar
  7. 7.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.CrossRefGoogle Scholar
  8. 8.
    Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefGoogle Scholar
  9. 9.
    Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526.CrossRefGoogle Scholar
  10. 10.
    Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRefGoogle Scholar
  11. 11.
    Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275–84.CrossRefGoogle Scholar
  12. 12.
    Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692–8.CrossRefGoogle Scholar
  13. 13.
    Facchiano E, Risio D, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol. 2012;19(9):2946–50.CrossRefGoogle Scholar
  14. 14.
    Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123–31.CrossRefGoogle Scholar
  15. 15.
    Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–52.CrossRefGoogle Scholar
  16. 16.
    Badgwell B, Blum M, Das P, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018;32(1):512.Google Scholar
  17. 17.
    Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24:3338.CrossRefGoogle Scholar
  18. 18.
    Chang E, Alexander HR, Libutti SK, et al. Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg. 2001;193(2):225–9.CrossRefGoogle Scholar
  19. 19.
    Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34(2):154–8.CrossRefGoogle Scholar
  20. 20.
    Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100(4):331–4.CrossRefGoogle Scholar
  21. 21.
    Ba MC, Cui SZ, Lin SQ, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16(15):1901–7.CrossRefGoogle Scholar
  22. 22.
    Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–85.CrossRefGoogle Scholar
  23. 23.
    Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.The University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations